RecruitingNot ApplicableNCT06766058
Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy.
Sponsor
National Cancer Centre, Singapore
Enrollment
300 participants
Start Date
Oct 22, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
ASTER is a multi-part study that aims to prospectively establish evidence for the implementation of aromatherapy as complementary therapy within cancer care in the Singapore context. ASTER 2 study evaluates how extracts from Asian aromatic plants with familiar aromas introduced as inhalation therapy can alleviate distress in breast cancer patients scheduled to undergo radiotherapy (RT).
Eligibility
Sex: FEMALEMin Age: 21 YearsMax Age: 99 Years
Inclusion Criteria4
- Aged 21 years old and above
- Confirmed diagnosis of breast cancer of any stage
- Scheduled to undergo radiotherapy for the first time
- Capable of providing informed consent
Exclusion Criteria5
- Physically or mentally incapable of providing verbal/written consent
- Known or suspected hypersensitivity/allergy to essential oils or any components of the formulations
- Airway hypersensitivity to fragrances, paint fumes or turpentine
- Taking medications for anxiety (e.g. benzodiazepines) before radiotherapy
- Pregnant, breastfeeding, or intending to conceive during study period
Interventions
OTHERCarrier oil
Inhaler stick containing 2 drops of carrier oil.
OTHERAsian plant extract blend
Inhaler stick containing 2 drops of Asian plant extract blend.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06766058
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
NCT0693085934 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations